注射用益气复脉辅治慢性心力衰竭患者的效果及对心功能和血液流变学的影响

doi:10.3760/cma.j.cn441417-20250331-19005

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (19): 3191-3195.DOI: 10.3760/cma.j.cn441417-20250331-19005

注射用益气复脉辅治慢性心力衰竭患者的效果及对心功能和血液流变学的影响

臧柯靓¹ 班芳¹ 张秋梅² 张恒亮³

¹商丘市立医院心血管内科，商丘 476100；²商丘市第一人民医院冠心病监护病房，商丘 476100；³南阳市中心医院心血管内科，南阳 473000

收稿日期:2025-03-31 出版日期:2025-10-01 发布日期:2025-10-24
通讯作者: 臧柯靓，Email：15738111769@163.com
基金资助:
2023年河南省医学科技攻关计划（LHGJ20230458）

Efficacy of Yiqi Fumai injection in treating patients with chronic heart failure and its impact on cardiac function and hemorheology

Zang Keliang¹, Ban Fang¹, Zhang Qiumei², Zhang Hengliang³

¹Department of Cardiovascular Medicine, Shangqiu Municipal Hospital, Shangqiu 476100, China; ²Coronary Care Unit, The First People's Hospital of Shangqiu, Shangqiu 476100, China; ³Department of Cardiovascular Medicine, Nanyang Central Hospital, Nanyang 473000, China

Received:2025-03-31 Online:2025-10-01 Published:2025-10-24
Contact: Zang Keliang, Email: 15738111769@163.com
Supported by:
2023 Medical Science and Technology Research Plan of Henan Province (LHGJ20230458)

摘要/Abstract

摘要：

目的　探讨注射用益气复脉辅助治疗慢性心力衰竭（CHF）患者的效果及对心功能、血液流变学的影响。方法　采用回顾性研究。选取2021年6月至2024年5月商丘市立医院收治的94例CHF患者临床资料，根据治疗方法不同分为对照组和观察组，每组47例。对照组男21例，女26例，年龄（63.29±4.17）岁，病程（8.12±3.51）个月。观察组男20例，女27例，年龄（62.02±4.52）岁，病程（9.15±3.24）个月。对照组在常规治疗基础上给予螺内酯胶囊治疗，观察组在对照组基础上联合注射用益气复脉治疗。两组均持续用药2周。比较两组临床疗效，治疗前、治疗2周后的中医证候积分、血液流变学指标、血清学指标［血清氨基末端B型脑钠肽前体（NT-proBNP）、血管内皮生长因子（VEGF）］、心功能指标［左心室收缩末内径（LVESD）、左心室舒张末内径（LVEDD）、左室射血分数（LVEF）］及不良反应。采用χ²、t检验进行统计分析。结果　观察组的总有效率高于对照组［97.87%（46/47）比85.11%（40/47）］，差异有统计学意义（χ²=4.919，P=0.027）。治疗2周后，观察组的中医证候主症、次症、总积分均低于对照组［（3.26±0.97、2.43±0.85、5.69±1.36）分比（6.43±1.24、4.25±0.76、10.68±2.07）分］，全血黏度高切、低切及血浆黏度、红细胞压积、纤维蛋白原、NT-proBNP、LVESD、LVEDD水平均低于对照组，VEGF、LVEF水平均高于对照组，差异均有统计学意义（均P<0.05）。两组均未出现明显不良反应。结论　注射用益气复脉辅助治疗CHF疗效显著，可明显缓解临床症状，改善血液流变学及血清学指标，促进心功能恢复。

关键词:

慢性心力衰竭, 注射用益气复脉, 螺内酯, 血液流变学, 指标

Abstract:

Objective　To explore the effects of injectable Yiqi Fumai on patients with chronic heart failure (CHF) and its impact on cardiac function and blood rheology. Methods　A retrospective study was conducted on 94 CHF patients treated at Shangqiu Municipal Hospital from June 2021 to May 2024. The patients were divided into a control group and an observation group based on different treatment methods, with 47 cases in each group. The control group included 21 males and 26 females, with an average age of (63.29±4.17) years and a disease duration of (8.12±3.51) months. The observation group included 20 males and 27 females, with an average age of (62.02±4.52) years and a disease duration of (9.15±3.24) months. The control group received spironolactone capsules on the basis of conventional treatment, the observation group received injectable Yiqi Fumai in addition to the treatment in the control group. Both groups continued the medication for 2 weeks. The efficacy of treatment, Traditional Chinese Medicine (TCM) syndrome scores before and after 2 weeks of treatment, blood rheology parameters, serological indicators [serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), vascular endothelial growth factor (VEGF)], cardiac function indicators [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)], and adverse reactions were compared. Statistical analysis was performed using χ² and t tests. Results　The overall effective rate in the observation group was higher than that in the control group [97.87% (46/47) vs. 85.11% (40/47)], with a statistically significant difference (χ²=4.919, P=0.027). After 2 weeks of treatment, the primary symptoms, secondary symptoms, and total scores of TCM syndromes in the observation group were lower than those in the control group [(3.26±0.97, 2.43±0.85, and 5.69±1.36) points vs. (6.43±1.24, 4.25±0.76, and 10.68±2.07) points]. The levels of whole blood viscosity (high shear, low shear), plasma viscosity, NT-proBNP, hematocrit, LVESD, fibrinogen, and LVEDD in the observation group were lower than those in the control group, while VEGF and LVEF levels were higher in the observation group, with all differences being statistically significant (all P<0.05). No significant adverse reactions were observed in either group. Conclusion　Yiqi Fumai injection is effective in the treatment of CHF, which can significantly relieve clinical symptoms, improve hemorheology and serological indexes, and promote the recovery of cardiac function.

Key words:

Chronic heart failure, Yiqi Fumai , Injection, Spironolactone, Hemorheology, Index

臧柯靓班芳张秋梅张恒亮.

注射用益气复脉辅治慢性心力衰竭患者的效果及对心功能和血液流变学的影响 [J]. 国际医药卫生导报, 2025, 31(19): 3191-3195.

Zang Keliang, Ban Fang, Zhang Qiumei, Zhang Hengliang.

Efficacy of Yiqi Fumai injection in treating patients with chronic heart failure and its impact on cardiac function and hemorheology [J]. International Medicine and Health Guidance News, 2025, 31(19): 3191-3195.

参考文献

[1] 孙静,蔡瑞,毛起超. 周亚滨教授治疗慢性心力衰竭之"四维理论"经验[J]. 中国医药导报,2022,19(30):132-136. DOI:10.20047/j.issn1673-7210.2022.30.30.
[2] Obokata M, Sorimachi H, Harada T, et al. Epidemiology, pathophysiology, diagnosis, and therapy of heart failure with preserved ejection fraction in Japan[J]. J Card Fail, 2023, 29(3): 375-388. DOI: 10.1016/j.cardfail.2022.09.018.
[3] 蔡申燕,骆天炯,周迎晨. 基于"通阳不在温,而在利小便"思路治疗慢性心力衰竭[J]. 江苏中医药,2022,54(3):12-15. DOI:10.19844/j.cnki.1672-397X.2022.03.006.
[4] 崔青林,李敬田. 螺内酯治疗慢性心力衰竭87例疗效观察[J]. 潍坊医学院学报,2002,24(4):312-312. DOI:10.3969/j.issn.1004-3101.2002.04.042.
[5] Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, et al. The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF[J]. Med Arch, 2023, 77(2): 105-111. DOI: 10.5455/medarh.2023.77.105-111.
[6] 何方,罗德金,曹湘云. 稳心颗粒联合螺内酯对慢性心力衰竭患者左室功能、运动耐力及VEGF、NT-proBNP的影响[J]. 临床和实验医学杂志,2023,22(19):2036-2039. DOI:10.3969/j.issn.1671-4695.2023.19.006.
[7] 李琳,曾逸笛,叶家豪,等. 基于益气养阴法探讨参麦注射液调控肠道菌群-TMAO-炎症轴防治慢性心力衰竭的思路与策略[J]. 湖南中医药大学学报,2023,43(7):1258-1262. DOI:10.3969/j.issn.1674-070X.2023.07.016.
[8] 刘晨萍,陈楚辞,袁晨越. 强心方治疗心肾阳虚型慢性心力衰竭回顾性队列研究[J]. 同济大学学报(医学版),2024,45(1):81-86. DOI:10.12289/j.issn.1008-0392.23378.
[9] 李智,李汶泽,万梅绪,等. 注射用益气复脉(冻干)对心血管系统的药理作用及机制研究进展[J]. 药物评价研究,2022,45(11):2386-2392. DOI:10.7501/j.issn.1674-6376.2022.11.029.
[10] 谢先余,蒋志坤,花继平. 注射用益气复脉(冻干)对老年性慢性心力衰竭(气阴两虚证)患者的疗效观察[J]. 药物评价研究,2022,45(12):2548-2554. DOI:10.7501/j.issn.1674-6376.2022.12.021.
[11] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 慢性心力衰竭基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(10):936-947. DOI:10.3760/cma.j.issn.1671-7368.2019.10.008.
[12] 国家中医药管理局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 459-461.
[13] Schou M, Petrie MC, Borlaug BA, et al. Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF program[J]. J Am Coll Cardiol, 2024, 84(3): 247-257. DOI: 10.1016/j.jacc.2024.04.038.
[14] 徐玉凤,傅咏华. 基于出院护理计划为指导的连续护理干预对慢性心力衰竭患者知识掌握及自我护理能力的影响[J]. 山西医药杂志,2022,51(12):1426-1428. DOI:10.3969/j.issn.0253-9926.2022.12.033.
[15] 马悦,喻正科,赵启,等. 喻正科从气机升降辨治慢性心力衰竭经验[J]. 中医药临床杂志,2024,36(2):242-245. DOI:10.16448/j.cjtcm.2024.0210.
[16] 刘丽华,张婧倩,赵颖,等. 慢性心力衰竭病人中医证型及性别与心冲击图的关系[J]. 中西医结合心脑血管病杂志,2023,21(5):779-783. DOI:10.12102/j.issn.1672-1349.2023.05.003.
[17] 王彬,顾磊. 注射用益气复脉(冻干)联合沙库巴曲缬沙坦治疗慢性心力衰竭疗效及对患者hs-cTnT、NT-proBNP及左心室功能的影响[J]. 药物评价研究,2023,46(8):1747-1752. DOI:10.7501/j.issn.1674-6376.2023.08.019.
[18] 郭贺杰,李雯,张亚娜. 益气复脉注射液辅治不稳定型冠心病心绞痛临床观察[J]. 实用中医药杂志,2025,41(3):550-552. DOI:10.3969/j.issn.1004-2814.2025.03.042.
[19] 张丽荣,闫洪超. 红参对卵巢储备功能减退大鼠卵巢储备功能和卵巢组织磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路的影响[J]. 安徽医药,2024,28(7):1323-1327,后插3. DOI:10.3969/j.issn.1009-6469.2024.07.011.
[20] 周晓洁,王琪,闫博文,等. 五味子对神经、精神疾病作用及机制的研究进展[J]. 中国药理学通报,2022,38(3):338-342. DOI:10.12360/CPB202107056.
[21] 常思潮,常惟智. 麦冬的药理作用及复方临床应用研究进展[J]. 光明中医,2023,38(12):2443-2446. DOI:10.3969/j.issn.1003-8914.2023.12.061.
[22] 张凤巧,李帅,李胜利. 益气复脉注射液联合呋塞米治疗DCM心力衰竭患者的效果[J]. 国际医药卫生导报,2023,29(6):768-772. DOI:10.3760/cma.j.issn.1007-1245.2023.06.006.
[23] 曹山山,滕伟,唐启卫. 芪参益气滴丸联合厄贝沙坦氢氯噻嗪对慢性心力衰竭患者心功能及血液流变学的影响[J]. 黑龙江医药科学,2025,48(6):49-52. DOI:10.3969/j.issn.1008-0104.2025.06.015.
[24] 苏布道,陈华,贺文帅. 瑞舒伐他汀钙联合美托洛尔治疗冠心病合并心力衰竭的机制[J]. 西北药学杂志,2023,38(1):145-149. DOI:10.3969/j.issn.1004-2407.2023.01.025.
[25] 孙洪洋,姜阳,王婷. 慢性心力衰竭患者心脏彩超参数、血浆cMyBP-C水平变化及临床意义研究[J]. 检验医学与临床,2025,22(2):198-202,209. DOI:10.3969/j.issn.1672-9455.2025.02.010.
[26] 韩琼,杨伟,高夏青. 心脏彩超诊断慢性心力衰竭的应用价值分析[J]. 临床和实验医学杂志,2022,21(7):774-777. DOI:10.3969/j.issn.1671-4695.2022.07.028.

注射用益气复脉辅治慢性心力衰竭患者的效果及对心功能和血液流变学的影响

Efficacy of Yiqi Fumai injection in treating patients with chronic heart failure and its impact on cardiac function and hemorheology

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李广洲王红雷贺洋胡翠陈艳浩. 扩大淋巴结清扫胰十二指肠切除手术治疗胰腺癌患者的效果 [J]. 国际医药卫生导报, 2025, 31(8): 1327-1331.
[2]	刘雪妮惠容容　邓庆. 多普勒超声与炎症指标诊断T2DM患者下肢血管病变的价值 [J]. 国际医药卫生导报, 2025, 31(8): 1337-1342.
[3]	罗春燕吴佳奇方晓敏黄颜怡肖惠明. 基于德尔菲法构建眼科门诊护理质量指标体系 [J]. 国际医药卫生导报, 2025, 31(7): 1217-1222.
[4]	李博迟洁高蒙. 利用临床特征与生化指标建立细菌性脑膜炎转归不良的风险预测模型 [J]. 国际医药卫生导报, 2025, 31(4): 663-668.
[5]	陈堃刘亚良秦书敏盛杰鑫杨琳郝阳. CT肌肉特征指标对结直肠癌患者化疗敏感程度的预测价值 [J]. 国际医药卫生导报, 2025, 31(16): 2761-2765.
[6]	曹雅程相超赵锦华刘耀刚涂成志丁圣. 圈套器冷切除术治疗结直肠息肉患者的效果 [J]. 国际医药卫生导报, 2025, 31(16): 2766-2769.
[7]	杜晓艳闫会丽韩建伦余蒙蒙. 阿托伐他汀联合阿利西尤单抗注射液对冠心病患者血脂指标的影响 [J]. 国际医药卫生导报, 2025, 31(15): 2525-2529.
[8]	陈学前雷莲莲周桂智. 支气管肺泡灌洗术对成人重症肺炎疗效及sICAM-1、IL-6水平的影响 [J]. 国际医药卫生导报, 2025, 31(15): 2568-2573.
[9]	薛峥峰刘庆钟红平李芳. KD合并MP感染患儿心肌功能与血清Lp-PLA2、NT-proBNP、PCT水平及凝血指标的关系 [J]. 国际医药卫生导报, 2025, 31(13): 2197-2201.
[10]	任传薇李会颖沈艳婷. 持续质量改进在老年癌痛患者管理中的应用 [J]. 国际医药卫生导报, 2025, 31(12): 2083-2088.
[11]	姜泽军汤胜宇杨红玲. 炎症标志物在慢性心力衰竭临床预后评估中的作用 [J]. 国际医药卫生导报, 2025, 31(1): 42-46.
[12]	李亚辉李彩蝶赵翔. 分阶段肺康复锻炼在成人急性呼吸窘迫综合征患者中的应用效果观察 [J]. 国际医药卫生导报, 2025, 31(1): 127-131.
[13]	张思思江淑贤范晨萌陈妙霞李莉莉. 肝衰竭内科治疗护理质量敏感指标的构建 [J]. 国际医药卫生导报, 2024, 30(9): 1559-1564.
[14]	陈若蒋蕾赵旭东陈倩倩. 神经外科重症合并吞咽功能障碍患者的肠内营养支持策略 [J]. 国际医药卫生导报, 2024, 30(7): 1217-1221.
[15]	辛田杜婷婷武鹏李宁. 手术风险自查护理在青光眼小梁切除术患者中的临床效果 [J]. 国际医药卫生导报, 2024, 30(5): 862-866.